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ow
nloaded fLysosomal storage disorders (LSDs) result from an enzyme deficiency within lysosomes. The systemic adminis-
tration of the missing enzyme, however, is not effective in the case of LSDs with central nervous system (CNS)-
involvement. Here, an enzyme delivery system based on the encapsulation of cross-linked enzyme aggregates
(CLEAs) into poly-(lactide-co-glycolide) (PLGA) nanoparticles (NPs) functionalized with brain targeting peptides
(Ang2, g7 or Tf2) is demonstrated for Krabbe disease, a neurodegenerative LSD caused by galactosylceramidase
(GALC) deficiency. We first synthesize and characterize Ang2-, g7- and Tf2-targeted GALC CLEA NPs. We study
NP cell trafficking and capability to reinstate enzymatic activity in vitro. Then, we successfully test our formula-
tions in the Twitcher mouse. We report enzymatic activity measurements in the nervous system and in accu-
mulation districts upon intraperitoneal injections, demonstrating activity recovery in the brain up to the








Lysosomal storage disorders (LSDs) are a large group of more than
70 clinically recognizedmetabolic disorders, which are individually rare
but collectively common (1:5000 live births). They result for the most
part from an enzyme deficiency within the lysosomes, which ultimately
causes accumulation of undegraded substrates. This storage process
leads to a broad spectrum of clinical manifestations depending on the
specific substrate and site of accumulation.Most LSDs showwidespread
tissue and organ involvement, with brain, viscera, bone, and connective
tissues usually affected. Brain disease is particularly prevalent, involving
two-thirds of all LSDs (1).
Krabbe disease [KD or globoid cell leukodystrophy; Online
Mendelian Inheritance in Man (OMIM) no. 245200] is a fatal pe-
diatric neurodegenerative LSD caused by deficient activity of the
enzyme galactosylceramidase (GALC; EC 3.2.1.46). GALC degrades
galactosylceramide, a major component of myelin, and other ter-
minal b-galactose–containing sphingolipids, including the cytotoxic
D-galactosylsphingosine [psychosine (PSY)] (2). GALC loss of function
causes increased PSY levels in neural tissues, leading to widespread
degeneration of oligodendrocytes and Schwann cells and subsequent
devastating demyelination. The disease is further characterized by
central nervous system (CNS) infiltration of macrophages, which turn
into multinucleated “globoid cells” (3).
In humans, KD is typically a neurodegenerative disease of early in-
fancy (95% of known cases), but there are examples inwhich it has been
diagnosed in older children and adults. The early infantile phenotype
onset is typically within the first 6 months of life and leads to death
by 2 years of age (4). No effective cure is currently available for KD.
The only clinically applied method, which only delays symptom pro-
gression, is bone marrow transplantation (BMT). This treatment, how-ever, is effective only if performed in the neonatal period, and the
recruitment of an adult donor often takes too long for the treatment
of a so rapidly progressive disorder. Yet, transplantation requires immu-
nosuppressant therapies that may even worsen the conditions of the
young patients (5).
Among other potential therapies, intracerebral gene therapy (GT)
has recently yielded good results in experimental models such asmouse
and dog (6, 7). Nevertheless, both BMT and GT need time to engraft
and create therapeutic effects, thus not allowing the effective prevention
of early nervous systemdamage. For this reason, a therapy that could be
promptly applied in the very first period after birth is required. To this
end, systemic enzyme replacement therapy (ERT)would be the best op-
tion (8), but the presence of the blood-brain barrier (BBB) forbids the
translocation of proteins like GALC (77 kDa) into the CNS. Only some
low–molecular weight (<400–500 Da) and small lipophilic molecules
are allowed to pass through the BBB (9).
In recent years, a lot of interest arose from the development of
enzyme-loaded nanosystems, which may enhance the efficacy of
ERT and minimize side effects using innovative and biocompatible na-
nomaterials. Enzyme encapsulation in biodegradable micelles, lipo-
somes, and polymer- and lipid-based nanoparticles (NPs) can protect
enzyme integrity and activity, eradicating some of the key limitations of
ERT, including immunologic reactions and degradation (8). It can also
enhance the pharmacological response by improving pharmacokinetics
and pharmacodynamics and allowing for a controlled release of the
payload (10). Moreover, the possibility of decorating the surface of
the nanocarrier with targeting molecules (peptides, aptamers, and anti-
bodies) promotes passage through biological barriers such as the BBB
and blood-ocular barrier (11).
Among the investigatedmaterials forNP synthesis, poly-(lactide-co-
glycolide) (PLGA) has received special attention, being a biocompatible,
nontoxic, and Food and Drug Administration–approved polymer for
intravenous administration in humans (12). However, successful en-
capsulation of proteins and enzymes in PLGA NPs is still an open
issue. We recently described (13) a new encapsulation strategy that
allows loading enzymes with excellent efficiency and activity retention.1 of 13
SC I ENCE ADVANCES | R E S EARCH ART I C L EIn particular, we reported a synthesismethod for a new enzyme delivery
platform based on cross-linked enzyme aggregates (CLEAs) en-
capsulation into PLGA NPs. We demonstrated that this system allows
encapsulation of different enzymes (PPT1, GALC, and glucosidase)
with excellent activity retention. Delivery efficiency and enzyme activity
recovery were validated in vitro using neuronal ceroid-lipofuscinosis
type 1 (NCL1) primary fibroblasts.
In the present work, we focused onGALC for testing in vivo enzyme
delivery into the brain. To this end, we synthesized and fully character-
ized three new formulations of GALCCLEA–loaded PLGANPs. These
NPs were functionalized with targeting peptides [Angiopep-2 (Ang2)
(14), g7 (15), or transferrin binding (Tf2) peptides (16)], aimed to allow
NPs to pass the BBB. At first, we studied NP cell uptake and trafficking
and their capability to reinstate enzymatic activity inmurinemodel cells
and in fibroblasts from patients with KD. Then, we tested our nanosys-
tem in vivo in the Twitcher (TWI) mouse, the spontaneous mouseDel Grosso et al., Sci. Adv. 2019;5 : eaax7462 20 November 2019model of theKD (17).We evaluated enzymatic activity recovery 4 hours
after NP intraperitoneal injection in different organs of the CNS and
peripheral nervous system (PNS), as well as in typical accumulation dis-
tricts. Moreover, we assessed the presence of targeted NPs in extracted
brains and livers by means of confocal fluorescence microscopy.RESULTS
Synthesis and characterization of targeted GALC CLEA NPs
For these experiments, three targeted versions of GALC CLEA–loaded
NPs were synthesized, each decorated with a different peptide for CNS
targeting (Fig. 1A). GALC CLEA NPs were produced with a two-step
protocol previously developed by our group and functionalizedwith the
targeting peptides Ang2, g7, or Tf2 with a preformulation approach
including a peptide-modified PLGA in the formulation. First, Ang2,
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Fig. 1. Targeted GALC CLEA NP synthesis and characterization. (A) Graphical summary of the experiment. Peptide-modified PLGA was produced by covalent linking of each
peptide to a previously activated form of PLGA. GALC CLEAs were obtained by precipitation of GALC in acetone in the presence of glutaraldehyde, resulting in Schiff base formation
between enzymemolecules. Last, targeted GALC CLEA NPs were obtained by nanoprecipitation. (B) Hydrodynamic Diameter of GALC CLEA NPs. Error bars represent the SEM of
four independently synthesized NP batches. (C) Zeta potential of GALC CLEA NPs. Error bars represent the SEM of four independently synthesized NP batches. (D) Encapsulation
efficiency of GALC CLEA NPs. Encapsulation efficiency is expressed as percentage of encapsulated GALCwith respect to the amount of enzyme used in each synthesis. Error bars
represent the SEM of four independently synthesized NP batches. (E) Activity yield of GALC CLEA NPs. Activity yield is expressed as percentage of specific activity (nanomole
substrate hydrolyzed in 1 hour by 1 mg of enzyme) with respect to the free unaltered enzyme. Error bars represent the SEM of four independently synthesized NP batches.2 of 13









each peptide was covalently attached to PLGA, exploiting the terminal
carboxylic acid on the polymer (18). Precisely, cysteine-terminated
Ang2 and Tf2 were linked to maleimide-activated PLGA, whereas
amine-terminated g7 was attached to N-hydroxysuccinimide
(NHS)–activated PLGA. Next, GALC CLEAs were first produced by
precipitation of the enzyme in acetone in the presence of glutar-
aldehyde, resulting in Schiff base formation and subsequent cross-
linking of the precipitated enzyme. Then, GALC CLEAs were
encapsulated into targeted PLGA NPs by nanoprecipitation. To this
end, GALC CLEAs, PLGA, and peptide-modified PLGA were mixed
in acetone and added dropwise to an aqueous solution of sodium
cholate. In this process, PLGA spontaneously precipitated as acetone
diffused into water, encapsulating CLEAs into NPs that could be
collected by centrifugation. Control nontargeted GALC CLEA–
loaded NPs were produced by encapsulation of CLEAs in nonmodi-
fied PLGA NPs.
Themain features of GALCCLEANPs are reported in Fig. 1 (B to
E). All the produced NPs showed a hydrodynamic diameter below
200 nm with small differences among the NP types, with GALC
Ang2 NPs and nontargeted NPs displaying the largest (191 ± 18 nm)
and the smallest (149 ± 6 nm) diameters, respectively. On the contrary,
the surface zeta potential was rather uniform among all NP types
(around −30 mV). GALC CLEAs were successfully encapsulated by
all the NP formulations, with encapsulation efficiencies ranging from
40 to 75%. TheNP formulation showing the best encapsulation efficien-
cy was GALC g7 NPs, whereas GALC Tf2 NPs led to the greatest en-
zyme loss during synthesis. The activity yield also varied among the
batches, with GALC Ang2 and GALC Tf2 NPs being the formulations
with highest GALC activity preservation.
Intracellular delivery of targeted NPs
Before testing the efficacy of GALC CLEA NP–mediated ERT, we
explored their cellular uptake and intracellular trafficking in primary
fibroblasts extracted from TWI and wild-type (WT) mice by means of
confocalmicroscopy and colocalization analysis. In particular, we inves-
tigated whether GALC CLEA NPs could be endocytosed by cells and
reach the right intracellular target of GALC, which is the lysosome
(19, 20). To this end, we produced a dual fluorescently labeled version
of each NP formulation used in this study (Ang2-, g7-, or Tf2-targeted
NPs and nontargetedNPs) by encapsulating ATTO 488–labeledGALC
CLEAs into ATTO 633–tagged PLGA NPs. We then incubated either
TWI or WT fibroblasts with NPs for 4 hours. Cells were subsequently
washed and incubated in fresh medium; after 24 hours, cells were fixed
and stained for lysosomes and nuclei. Four-color confocal fluorescence
microscopy was lastly carried out to assess the intracellular localization
of both NPs and GALC independently (Fig. 2A). A first visual image
analysis showed that both GALC and NPs extensively colocalized in ly-
sosomes of both TWI (Fig. 2B) andWT (fig. S1) fibroblasts. Moreover,
the enzyme was found in lysosomes independently from the presence
and the identity of the targeting ligand in TWI and WT cells as well.
These qualitative results were confirmed by a quantitative colocaliza-
tion analysis that we performed by calculating the Manders’ co-
efficient for GALC/lysosomes and NP/lysosomes. As shown in Fig.
2C, this coefficient was around 0.8 both for GALC/lysosomes and
PLGA/lysosomes overlap, proving that the enzyme and NPs are
highly colocalized with the lysosomes. Overall, these data demonstrate
that GALC CLEA NPs are effectively endocytosed by GALC-deficient
cells into lysosomes, the desired cell compartment allowing for optimal
GALC action.Del Grosso et al., Sci. Adv. 2019;5 : eaax7462 20 November 2019NP-mediated enzymatic activity recovery in vitro
After the demonstration of the capability of GALC CLEANPs to reach
cell lysosomes, we tested whether they could restore GALC enzymatic
activity in deficient cells in vitro. To pursue this aim, we used murine
TWI and WT cells and fibroblasts from patients with KD and healthy
donors (HDs) (see Material and Methods for details on cell culture
and treatments).
First, we performed a dose-response enzymatic recovery experiment
in GALC-deficient (TWI) murine cells to find a useful dose range to
approximately reach the GALC enzymatic activity of healthy cells.
WT cells were used as healthy control. Specifically, we treated TWI cells
with increasing doses of targeted or nontargeted GALC CLEA NPs,
which corresponded to the following doses of enzyme: 0.75, 1.5, 3.0,
and 6.0 U. Intracellular GALC activity was tested 4 hours after treat-
ments. Control TWI cells were also treated with equivalent doses of free
recombinantmurine GALC (rm-GALC). See Fig. 3A for an overview of
the experimental plan.
The first important observation was that the administration of
enzyme-loaded NPs led to substantial GALC activity (>25% with re-
spect to WT cells) within TWI cells regardless the tested formulation/
dose.More specifically, the enzymatic activity increasedwith the dose in
all cases (Fig. 3B). Focusing on targeted formulations, the trend was
quite similar for Ang2 and g7 NPs. In both cases, only the 0.75-U dose
returned a GALC intracellular activity significantly different from that
of WT (taken as 100%) cells. With the dose of 1.5 U of NPs, instead,
GALC activity was approximately 50% of the WT conditions, and by
administrating 3 U, the activity reached that of WT cells. At the max-
imal dose (6 U), the WT activity was even exceeded. Tf2 NPs behaved
similarly to Ang2 and g7 NPs at the lowest and the highest doses,
whereas intermediate doses yielded similar recovery to the lowest dose.
Expectedly, nontargeted NPs were internalized with efficiency compa-
rable to targeted NPs being significantly different from the WT
conditions for the two lowest doses. The third dose recovered the
WT activity, and the last one overexceeded it. Cells treated with free
GALC showed increased activity upon treatment, but this effect was less
pronounced than in the case ofNPs.NPs not loadedwithGALCCLEAs
(empty NPs in Fig. 3C) did not yield any detectable enzymatic activity.
The basal GALC activity of TWI fibroblasts (TWI-UT in Fig. 3C) was
approximately indistinguishable from the background level of the ex-
perimental setting, as already reported (21).
Given that the 3-Udose ofNPs demonstrated the ability to success-
fully recover the WT activity in most of the formulations without
overexceeding the WT level, it was selected for the subsequent time-
response experiments. In this case, bothmurine and human cells were
treatedwith targeted and nontargetedNPs orwith free rm-GALC.After
4 hours, cells were washed and added with fresh medium. GALC enzy-
matic activity was then assayed 24 or 96 hours after treatments (see the
experimental plan in Fig. 4A).
Murine cells treated with targeted or nontargeted NPs successful-
ly maintained approximately the WT enzymatic activity for 24 and
96 hours, except for nontargeted NPs at the time point of 96 hours.
Moreover, activity promoted by g7- and Tf2-targeted NPs signifi-
cantlywent beyond theWT levels. The rm-GALC–treated cells, instead,
reached the WT activity only after 96 hours and only in this case we
measured a significant difference between 24 and 96 hours within the
same treatment.
The same experiments were carried out with KD patient fibroblasts
having the common 30-kb deletion in the GALC gene (30kbD in Fig.
4D). Cells treated with targeted or nontargeted NPs showed similar3 of 13
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ATTO 488 GALC CLEA-
loaded ATTO 633 NPs
Fig. 2. Intracellular localization of targeted GALC CLEA NPs. (A) Graphical summary of the experiment. TWI or WT primary fibroblasts were incubated with fluores-
cently labeled ATTO 488 GALC CLEA-loaded ATTO 633 NPs for 4 hours and then washed and added with fresh medium. After 24 hours, cell lysosomes were stained, and
cells were fixed and imaged with a confocal microscope. (B) Confocal imaging. Representative confocal images of TWI fibroblasts treated with fluorescently labeled GALC
Ang2 NPs, GALC g7 NPs, GALC Tf2 NPs, or GALC NPs. From the left to the right column: GALC (green, stained with ATTO 488), NPs (red, stained with ATTO 633), lysosomes
(blue, stained with LysoTracker Red DND-99), nuclei (yellow, stained with DAPI), superimposition of GALC, NPs, lysosomes, and nuclei fluorescence and superimposition of
all channels with bright-field (BF) images. Scale bars, 10 mm. (C and D) Colocalization analysis. Manders’ coefficient of GALC/lysosomes and NPs/lysosomes overlap in TWI
cells treated with GALC CLEA NPs. (E and F) Manders’ coefficient of GALC/lysosomes and NPs/lysosomes overlap in WT cells treated with GALC CLEA NPs.Del Grosso et al., Sci. Adv. 2019;5 : eaax7462 20 November 2019 4 of 13









activity to that of cells fromHDs, except for those treated with g7- and
Tf2-targeted NPs after both 24 and 96 hours, whose activities were
significantly higher than the HD level. In the case of Tf2-targeted
and nontargeted NPs, the activity resulted significantly higher after
96 hours compared to the 24-hour time point. Free rm-GALC–treated
cells reachedHD levels after 24 hours, but activity decreasedwith time,
resulting in an opposite trendwith respect towhat was reported for the
murine cells. The GALC activity of TWI and 30kbD cells was not dis-
cernable from the background at both time points. (Fig. 4, C and E).
Together, these data demonstrate that GALCCLEANPsmaintain en-
zymatic activity upon cellular uptake and that they can completely re-
instate GALC activity in TWI and KD patient cells as well.
NP-mediated enzymatic activity recovery in vivo
The next step was to test GALC CLEA NPs as therapeutic agents for
enzymatic activity recovery in the brain of the TWImouse. Before these
experiments, the stability of the encapsulated enzyme in the presence ofDel Grosso et al., Sci. Adv. 2019;5 : eaax7462 20 November 2019serum proteins was evaluated. To this end, to mimic a biological fluid,
we incubated all kinds of NPs used in the study in amedium containing
50% fetal bovine serum and studied the kinetics of drug release. At spe-
cific time points, we measured the GALC activity both in the medium
(due to the released enzyme) and within the NP (due to the enzyme not
released yet). The release kinetics of GALC CLEAs was only slightly
affected by the presence of serum proteins. Specifically, in the presence
of proteins, around 50% of the payload were released within the first
24 hours (fig. S3A), whereas in serum-freemedium, NPs could retain
60% of the enzyme in the same time window (fig. S3B). One should
also note that the incubation of free nonencapsulated GALC in the
presence of serum proteins led to a marked loss of activity already
after few hours. This confirms that although the protein corona had
an influence on the release kinetics of the payload, as expected (22), the
encapsulation into NPs is a fundamental requirement not only to al-
low the right targeting but also to consent the enzyme to reach the
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Fig. 3. In vitro ERT: Dose-response experiment. (A) Graphical summary of the experiment. GALC-deficient primary fibroblasts (derived fromTWImice)were treatedwith GALC
CLEA NPs. After 4 hours, GALC activity was measured on cellular lysates by 6-hexadecanoylamino-4-methylumbelliferyl-b-D-galactopyranoside (HMU-bGal) assay. (B) Dose-
response experiment results. Cells were treatedwith targetedGALCCLEANPs (GALCAng2NPs, GALC g7NPs, or GALCTf2NPs), with nontargetedNPs (GALCCLEANPs), orwith
the free rm-GALC (GALC). For every treatment, four doses were tested: 0.75, 1.50, 3.0, and 6.0 U [unit (U) = amount of enzyme that catalyzes 1 nmol of substrate per hour].
Results are expressed in unit per microgram and reported in percentage of the activity of theWT cells [(U/mg) = unit of enzyme per microgram of cell lysate]. *P < 0.05 specific
treatment versus WT, one-way analysis of variance (ANOVA) (Dunnett’s multiple-comparisons test), means ± SEM (n = 3). (C) Controls. For control, NPs nonloaded with GALC
CLEAs (empty NPs) were also administered to the cells. WT- and TWI-untreated cells activity is also showed. Means ± SEM (n = 3).5 of 13









of active enzyme to the brain in vivo, the mice were systematically
administered with the NPs, and the presence of active GALC in key
CNS and PNS organs was evaluated by means of enzymatic activity
measurement and confocal fluorescence microscopy. This experiment
was carried out in youngmice (P19 to P21) before symptom onset (17).
Thus, we first synthesized targeted and nontargeted GALC CLEA
NPs labeled with the fluorophore ATTO 633 to allow visualization of
NPs in extracted tissues (see the experimental plan in Fig. 5A and
Materials andMethods for further details). Then, TWImice were treated
with NPs or with free rm-GALC via a single intraperitoneal injection.
After 4 hours,micewere euthanized by transcardial phosphate-buffered
saline (PBS) perfusion to thoroughly wash blood vessels, and organs
were extracted for characterization. In particular, we investigatedGALC
activity in representative organs of the CNS and PNS (brain and spinalDel Grosso et al., Sci. Adv. 2019;5 : eaax7462 20 November 2019cord and sciatic nerves, respectively) and in typical accumulation organs
(liver and kidneys). GALC activity was assayed and compared with the
activity of the sameorgans extracted fromcontrolmice [nontreatedWT
mice (WT-UT), nontreated TWImice (TWI-UT), and nontreated het-
erozygous (HET) mice (HET-UT) mice; see the legend in Fig. 5B]. The
presence of NPswas then investigated by fluorescence confocal imaging
in paraformaldehyde (PFA)–fixed tissues. Mice were divided in five ex-
perimental groups (see again legend in Fig. 5B): WT-UT, HET-UT,
TWI-UT, TWI treated with targeted NPs (TWI Targ-NPs), and TWI
treated with nontargeted NPs or with rm-GALC (TWI Controls). To
further assess the reproducibility of results, we tested two independently
synthesized NP batches for each NP type (lot a and lot b; Fig. 5B).
As reported in Fig. 5C, GALC activity raised up to the 42 ± 4% of the
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Fig. 4. In vitro: ERT time-response experiment. (A) Graphical summary of the experiment. GALC-deficient primarymurine (from TWImice) and human (from patients with KD
withGALC 30kbD) fibroblastswere treatedwith a single dose [3.0 U; unit (U) = amount of enzyme that catalyzes 1 nmol of substrate/hour] of targetedGALC CLEANPs (GALCAng2
NPs, GALC g7 NPs, or GALC Tf2 NPs), nontargeted NPs (GALC CLEANPs), or with the free rm-GALC (GALC). Four hours later, cells were incubated with freshmedium. GALC activity
was measured in the cell lysates 24 or 96 hours later by HMU-bGal assay. (B) NPs mediated ERT in GALC deficient mouse cells. Results are expressed in unit per microgram and
reported as percentage of the activity of the WT cells (U/mg = unit of enzyme per microgram of cell lysate). *P < 0.05 specific treatment versus WT, one-way ANOVA (Dunnett’s
multiple comparisons test). #P < 0.05 GALC 96 hours versus GALC 24 hours, Student’s t test, means ± SEM (n = 3). (C) Controls. WT and TWI untreated cells activity at 24 and
96 hours. Means ± SEM (n = 3). (D) NPs mediated ERT in GALC deficient human cells. Results are expressed in unit per microgram and reported in percentage of the activity
of the healthy (HD, human donor) cells (U/mg = unit of enzyme per microgram of cell lysate). *P < 0.05 specific treatment versus WT, one-way ANOVA (Dunnett’s multiple
comparisons test). #P< 0.05 GALC Tf2 NPs 96 hours versus GALC Tf2 NPs 24 hours and ##P< 0.01GALCNPs 96 hours versus GALCNPs 24 hours, Student’s t test,means ± SEM
(n = 3). (E) Controls. HD and 30kbD untreated cells activity at 24 and 96 hours. Means ± SEM (n = 3).6 of 13
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GALC CLEA-loaded ATTO 633 NPs
Fig. 5. In vivoNPmediatedERT in the TWImice. (A) Graphical summaryof theexperiment. TWImicewere treatedwith targetedGALCCLEAATTO633NPs (GALCAng2NPs,GALC
g7 NPs, or GALC Tf2 NPs), nontargeted GALC CLEA ATTO 633 NPs (GALC CLEA NPs), or with the free rm-GALC (GALC). Four hours later mice were euthanized, and GALC activity was
assayed in extracted brain, sciatic nerves, spinal cord, kidneys, and liver by HMU-bGal assay. (B) Legend. Untreated: WT (WT-UT), heterozygous (HET-UT), and TWI (TWI-UT). Targeted
GALC CLEA ATTO 633 NPs (TWI Targ-NPs): TWI-GALC Ang2 NPs (lot a and lot b), TWI-GALC g7 NPs (lot a and lot b), and TWI-GALC Tf2 NPs (lot a and lot b). Control treatments (TWI
Controls): GALCCLEAATTO633NPs (TWI-GALCNPs lot a and lot b) and free rm-GALC (GALC-lot a and lot b). (C) Brain GALC activity. ***P<0.001HET versusWT; ****P<0.0001 TWI, TWI
Targ-NPs, andTWIControls versusWT;+P<0.05TWIversusHET; #P<0.05TWIControls versus TWI; ####P<0.0001TWITarg-NPsversus TWIone-wayANOVA (Tukey’s test).Means±SEM
(n=3 to12pergroup). (D) LiverGALCactivity. **P<0.01TWIversusWTand#P<0.05TWIControls versusTWI, one-wayANOVA (Tukey’s test). ^P<0.05TWITarg-NPsversusWTand^^P<
0.01TWI Targ-NPs versus TWI, Student’s t test.Means±SEM(n=3 to6pergroup). (E) KidneyGALCactivity. ***P<0.001TWI andTWIControls versusWTand****P<0.0001TWI Targ-NPs
versusWT, one-wayANOVA (Tukey’s test).Means± SEM (n=3 to6per group). (F) Sciatic nerveGALCactivity. Results are expressed in unit permicrogramand reported aspercentageof
theWTactivity (U/mg=unit of enzymepermicrogramof cell lysate). ****P<0.0001all groups versusWT, +P<0.05 TWI versusHET, ++P<0.01WT, TWI Targ-NPs andTWIControls versus
HET, one-wayANOVA (Tukey’s test).Means±SEM (n=3 to8per group). (G) Spinal cordGALCactivity. ****P<0.0001HET, TWI Targ-NPs andTWI Controls versusWT, +P<0.05 TWI Targ-
NPs versusHET, and++P<0.01TWI andTWIControls versusHET, one-wayANOVA (Tukey’s test).Means±SEM(n=3 to7pergroup). (C toG)Results are expressed inunit permicrogram
and reported in percentage of the WT activity (U/mg = unit of enzyme per microgram of cell lysate). (H) Confocal imaging. Representative confocal images of brains and livers of the
treated TWImice. NPs are shown in red in the brains of themice administered with the functionalized targeted GALC CLEA ATTO 633 NPs (GALC Ang2 NPs, GALC g7 NPs, or GALC Tf2
NPs), while they are not present in the brain of the mice treated with the nontargeted GALC CLEA ATTO 633 NPs (GALC CLEA NPs). All livers present NPs. Scale bars, 5 mm.Del Grosso et al., Sci. Adv. 2019;5 : eaax7462 20 November 2019 7 of 13






targeted NPs. This value was significantly higher with respect to the ap-
proximately undetectable activity of the TWI-UT and reached the value
of the HET-UT (45 ± 8%), which represents a condition for which the
disease does not manifest. TWI Controls instead reported a lower
median value not significantly different from the TWI-UT, indicating
that GALC could not be transported into the brain.
We detected a significantly higher activity in the liver in both TWI
Targ-NPs and TWI Control mice (Fig. 5D) with respect to the TWI-
UT. This activity had likewise a higher median value for TWI Controls
with respect to TWI Targ-NPs, indicating greater liver accumulation in
the case of nontargeted NPs and of rm-GALC.
Kidneys showed a similar trend as the liver, but values of TWI Targ-
NPs and TWIControls mice remained lower compared to the liver, not
reaching the HET-UT and not being significantly different from the
TWI-UT (Fig. 5E). Concerning sciatic nerve and spinal cord, instead,
we did not observe any significantly detectable GALC activity neither in
TWI Targ-NPs nor in TWI Controls (Fig. 5, F and G).
Last, we visualized the presence of NPs in the brain and liver by flu-
orescence confocal microscopy. As shown in Fig. 5H, we could detect
the presence of fluorescently labeled NPs in the brain of mice treated
with the three differently targeted GALC CLEA NPs. On the contrary,
we could not find anyNP fluorescence signal formice treated with non-
functionalized NPs. Livers were taken as positive controls and, as
expected, presented a clear NP fluorescence both in the case of mice
treated with targeted and nontargeted NPs.
Together, these data demonstrate that targeted GALC CLEAs NPs
can induce GALC enzymatic activity via systemic administration in
TWI brains up to the level required for the disease not to manifest. As
expected, the presence of NPs was detected also in accumulation organs,




In this study, we aimed to investigate the efficacy of CNS-targeted
GALC-loaded biodegradable NPs as ERT agents for KD both in vitro
and in vivo. The final objective of this work was to determine whether
the targeted versions of our drug delivery system could reach the CNS
of the mouse model for KD and promote enzymatic activity recovery
in the brain, where GALC activity is most needed (23).
We tested three different peptides with potential as CNS-targeting
agents, namely, Ang2, g7, and Tf2. Ang2 is a 19–amino acid peptide that
promotes brain targeting as it binds the low-density lipoprotein receptor–
related protein 1 (14). The efficacy of this peptide as a CNS-targeting
agent has been extensively demonstrated with the Ang2-paclitaxel
conjugate ANG1005, currently not only in preparation for the phase 3
clinical trial (24) but also in Ang2-modified nanostructures, including
NPs (25). The g7 peptide is a glycosylated 7–amino acid–long peptide
derived from the synthetic opioid peptide MMP-2200. Polymeric NPs
bearing g7 peptide on the surface have been shown to cross the BBBwith
a mechanism that is still unclear, probably involving membrane-
membrane interactions and micropinocytosis-related processes (15).
Recently described peptide Tf2 allows indirect targeting of the transferrin
receptor by recognizing transferrin and has the potential to target the
CNS, given the high density of the transferrin receptor on the BBB (16).
We modified our previously developed NP formulation (13) based
on CLEAs formation and encapsulation into PLGANPs with each one
of these three peptide ligands. The presence of targeting ligands on the
NP surface led to an increase of the NP hydrodynamic diameter, par-
ticularly for NPs functionalized with the Ang2 peptide.Del Grosso et al., Sci. Adv. 2019;5 : eaax7462 20 November 2019Although all the formulations could successfully encapsulate GALC,
encapsulation efficiency varied among theNP compositions. Ang2- and
Tf2-functionalized NPs showed a lower encapsulation efficiency com-
pared to g7-targeted NPs (60, 39, and 74%, respectively). Further eva-
luations are required to rationalize this observation, but it is worth
noting that both Ang2 and Tf2, which show lower encapsulation effi-
ciency, are also positively charged at neutral pH and have a higher iso-
electric point (9.33 and 9.08, respectively, versus 5.98 of g7). It is possible
that unfavorable electrostatic interactions take place during the enzyme
encapsulation process, leading to a poorer outcome. However, Ang2
and Tf2 NPs resulted in a higher activity yield of GALC CLEAs (61
and 67%, respectively) compared to GALC g7 NPs (37%). Even in this
case, the different peptide environment could lead to different exposure
of the enzyme to the outer medium or cause undesired interactions be-
tween the targeting peptide and the enzyme. All in all, despite small dif-
ferences in terms of encapsulation efficiency and activity yield, the
presence of targeting ligands did not represent an obstacle in the en-
capsulation of active GALC CLEAs in NPs of suitable size (26).
Before testing the potential of the NP formulations as ERT candi-
dates, we verified that all NP types could enter cells and reach the intra-
cellular target of GALC, which is represented by lysosomes, a key point
to be investigated since endocytic route and signaling can be severely
altered in most LSDs (20). Confocal images and colocalization analysis
confirmed that all the NPs used in this study were taken up by cells and
were localized into lysosomes 24 hours upon treatment. This was
independent of the type of ligand and also of the type of cell, since sim-
ilar results were obtained in TWI andWT fibroblasts. This means that,
while the targeting peptides should address NPs to a certain district in
the organism, at the cellular level, they do not affect the expected fate of
NPs, which in this case leads to the endolysosomal route (27). Together,
our results indicate that GALC CLEA NPs can successfully vehiculate
the enzyme inside cells and accumulate in the lysosomes, where GALC
is supposed to perform its physiological activity, and that the preferred
localization of delivered GALC in the lysosomes is not affected by the
presence of targeting ligands on the carrier’s surface.
Thus, we proceeded with testing the ability of all NPs formulations
to deliver enzymatically active GALC in cells. A dose-response experi-
ment revealed that all formulations could promote enzymatic activity in
primary murine GALC-deficient cells in a dose-dependent manner.
The recombinant enzyme administered alone provided cells with an
activity that was always lower than the one resulting from the cor-
responding NP dose. NP doses of 3 and 6 U allowed performing ef-
ficient ERT in vitro, bringing enzymatic cell activity equal or even higher
than the physiological activity of healthy cells, while not even the highest
dose of free rm-GALC could induce WT activity. These data prove the
effectiveness of our NPs to deliver GALC inside cells in an active form
and in a more efficient way if compared to the nonencapsulated en-
zyme. This behavior can be probably attributed to the known ability of
polymeric NPs to protect the enzyme before it reaches the lysosomes
(28) and to the capability of controlling the release of their cargo at the
lysosomal acidic pH (29). Moreover, a time-response experiment
showed that targetedNPs canmaintain constantGALC activity (equal
or higher than WT) between 24 and 96 hours after treatment. Nontar-
geted NPs, instead, were affected by an activity decrease at t = 96 hours.
These results suggest that targeting agents could enhance NPs persist-
ence inside cells (30). Free rm-GALC, rather, yielded less than 50% of
WTactivity after 24 hours and reached theWT level only after 96 hours.
These in vitro data add important information to the very little knowl-
edge present in the literature about the suitability of polymeric NPs for8 of 13









ERT.Todate, only a fewworks have investigated the capability of PLGA
NPs to deliver functional enzymes, and only in vitro (13, 28). In this
context, our results confirm the potential of NPs made of this material
for enzyme delivery in vitro.
Given the very promising in vitro data, we proceeded with the testing
of our NP formulations in vivo in the TWI mouse, an authentic mouse
model of KD. TWI mice are by far the most commonly used murine
model in KD research, owing to the fact that this model closely recapitu-
lates human conditions such as undetectable GALC activity, PSY accu-
mulation in CNS and PNS, white matter degeneration, and the presence
of globoid cells. We treated TWI mice intraperitoneally with a single NP
injection to later assay the GALC activity inside different organs (of CNS
or PNS and in accumulation organs). We preliminarily carefully evalu-
ated different routes of drug administration, and we decided to use intra-
peritoneal injection given that is the predominantly used method for
systemic drugs administration in smallmice and that allows administering
large volumes of fluid safely. As expected, we found substantial GALC
activity in the examined accumulation organs (10, 31). Both targeted
(Ang2, g7, or Tf2) GALC CLEA NPs and controls (nontargeted NPs
and rm-GALC) accumulated in a similar amount in the liver and kid-
neys 4 hours after injection. These generally high liver accumulations
confirm the effectiveness of intraperitoneal injection. Intraperitoneally
injected drugs, indeed, are primarily absorbed by mesenteric vessels,
which drain into the portal vein, pass through the liver, and lastly reach
the systemic circulation (32). Regarding the brain, instead, we found
that mice treated with targeted NPs displayed a GALC activity that
was approximately equal to the activity of the HET-UT mice (hetero-
zygous mice for GALC mutation). This is a key finding if considered
that heterozygous mice are characterized by a completely healthy phe-
notype. The same is valid for human carriers of GALCmutations. This
result is even more appealing, considering that brains of mice treated
with nontargeted NPs or with the free enzyme instead did not show
any significant GALC activity increase. The fact that GALC activity
was not found in the brains of mice treated with nontargeted NPs
but was instead present in their livers confirms that, after reaching sys-
temic circulation, BBB passage can be attributed to the mechanism of
the specific targeting peptides, which have been already extensively inves-
tigated by us and others (14–16). Although some studies demonstrated
the ability of different types of NPs to reach the brain, this is the first time
that a nanovector is shown to deliver a functional enzyme into the brain
of an LSD model. Several efforts have been made to exploit certain cell
receptors to allow a free native or modified enzyme to pass the BBB, but
with not very promising results (33, 34). Even if the enzyme could reach
the brain, in fact, it would be rapidly metabolized by cells, causing the
need for very frequent injections from the perspective of clinical treat-
ment. Despite the fact that ERT with free recombinant enzymes is the
most widely applied clinical method to treat non-CNS–involved LSDs,
it requires long-term and frequent treatments, resulting in expensive
therapies that are not free from side effects, including immunoreactions
(35). In this context, the possibility to perform ERT with the enzyme
encapsulated in a safe nanovector is definitely appealing, as it could pro-
tect and slowly release the enzyme, thus minimizing some of the classical
ERT disadvantages.
Concerning the other analyzed tissues of the nervous system (the
spinal cord and sciatic nerve), neither enzyme-loaded NPs nor the re-
combinant enzyme could induce a significant GALC activity increase.
This is actually not unexpected. It is known indeed that efficient drug
delivery of therapeutic doses to these districts can be difficult to
achieve, owing to neuroanatomy issues and the restrictiveness of theDel Grosso et al., Sci. Adv. 2019;5 : eaax7462 20 November 2019blood-nerve barrier (36). A time longer than 4 hours would be likely
necessary to appreciate an elevation of the enzyme activity also in
these areas. There is also the possibility that different targeting strate-
gies may be required. Specific studies to address this point will be nec-
essary, being that the involvement of PNS is another typical feature of
KD and many other LSDs.
Two other important aspects that deserve to be underlined concern
interbatch reproducibility and the effect of cell sex on uptake of NPs.
Regarding the first one, all the in vivo experiments of this work were
carried with two different NP batches, each one independently synthe-
sized (i.e., in different days), with lots of different recombinant enzyme.
Results were perfectly consistent among the two batches. This observa-
tion gives an adjunctive strength to our approach, demonstrating the
reproducibility also among different batches of the produced drug. In-
terbatch reproducibility is indeed a very critical point regarding NPs in
general. For this reason, for example, many efforts have been recently
made to construct chips capable of automatically synthesizing polymer-
ic NPs in a very reproducible way (37). Cell sex, instead, is an interesting
overlooked factor, which can affect NP uptake by cells. Recently, in fact,
Serpooshan and co-workers demonstrated that cell sex leads to differ-
ences in quantum dot uptake between male and female human amni-
otic stem cells and primary fibroblasts (38). These findings lay the
foundation for the fact that variations existing in the production of para-
crine factors (as proteins or hormones) by male and female cells may
have the capacity to modify the protein corona of NPs, potentially
affecting NP cell interactions. However, mice treated with our targeted
NPs formulations did not report significant different outcomes between
male and female animals. Targeting peptides, thus, seem to promote
BBB translocation in a sex-independent manner, in accordance with
the fact that also enzyme release from our targeted NPs is not markedly
affected by the presence of the protein corona. Nevertheless, given the
difference in cell-secreted molecules that can occur between organisms
with different sexes during life, a longitudinal study of this aspect would
be desirable in view of an effective treatment.
Last, to underline the potential of clinical translatability of this drug
delivery system, we also performed a test in human cells derived from
patients with KD carrying the 30-kb deletion in the GALC gene, one of
the most common mutations causing KD (39). NPs revealed to be able
to carry enzymatically active GALC very efficiently also into human
cells, providing them with a GALC enzymatic activity that was much
higher than that of healthy cells up to 96 hours after the treatment. For
comparison, free rm-GALC could not even provide 50% of the activity
of healthy cells. This confirms the potential of GALC CLEA NPs for
ERT also in a human KD physiological environment.
In view of a clinical translation, a possible technical limitation that is
also common to other ERT approaches for other rare diseases might be
the availability of a large amount of drug allowing for treatment of the
patient for a lifetime. Producing recombinant enzymes from eukaryotic
cells, in fact, remains a quite expensive process (40). If this was the case,
NP-mediated ERT could be decisive if used as a sort of “buffer therapy”
to be promptly applied to the child immediately after birth for a limited
period of time, in combination with other therapeutic approaches. In
this way, a physiological enzyme activity would avoid nervous system
damage before the “long-term therapy” (most likely GT) can engraft and
provide its therapeutic effect (41). Last, we should stress that developing a
therapy preventing all neural damages is a markedly challenging task in
KD. It is indeed very rapidly progressing, with a median age of symptom
onset of 4 months andmedian time to diagnosis after onset of 3 months.
Therefore, to have a chance of success, it is imperative that therapy must9 of 13
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Consequently, also a deeper understanding of disease progression in
early-onset KD is critical for developing treatments, designing clinical
trials, and evaluating outcomes.
In conclusion, with this study, we demonstrated the capability of tar-
geted polymeric NPs to perform delivery of a protein into the brain of a
murine model of LSD, overcoming the BBB and delivering functional en-
zyme in a therapeutically relevant amount. This effective approach opens
new exciting therapeutic opportunities not only for all CNS-involved LSDs
with no cure available to date but also for all disorders, which could benefit










PLGA (Resomer RG 503H and Resomer RG 752H) was purchased
from Sigma-Aldrich and used as received. ATTO 488–NHS ester and
Atto 633 amine were purchased from ATTO-TEC GmbH (Germany)
and used as stock solutions (10 mg/ml) in dimethyl sulfoxide (DMSO).
All other chemicals were purchased fromSigma-Aldrich, unless oth-
erwise specified. All chemicals were used as received.
Methods
PLGA-NHS synthesis
PLGA was activated via NHS 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide (EDC) chemistry. PLGA (0.05 mmol) were dissolved
in 5 ml of anhydrous dichloromethane (DCM) under nitrogen atmo-
sphere, and 0.5mmol of NHS was added. Then, 0.5 mmol of EDC-HCl
and 0.6mmol of triethylamine (TEA)were added. The reactionmixwas
stirred for 18 hours at room temperature, and the product was precip-
itated with methanol and collected by centrifugation. The final product
was washed twice withmethanol, then characterized by 1HNMR (nuclear
magnetic resonance) in CDCl3, and stored at −20°C until use. Character-
ization: 1H NMR (300 MHz, CDCl3; Bruker Avance 300 spectrometer):
dPLGA-NHS = 5.2 parts per million (ppm) [─OCH(CH3)COO─],
4.8 ppm [─OCH2COO─], 2.9 ppm [─COCH2CH2COON─), and
1.6 ppm [─OCH(CH3)CO─].
PLGA-Mal synthesis
PLGA-NHS was further modified with a maleimide group to allow the
reaction with cysteine-terminated peptides. PLGA-NHS (0.05 mmol)
was dissolved inDCM, and 0.1mmol ofN-(2-aminoethyl)maleimide tri-
fluoroacetate was added together with 0.11 mmol of TEA. The reaction
mix was stirred for 2 hours at room temperature, and the product was
precipitated with methanol and collected by centrifugation. The final
product was washed twice with methanol and characterized by
1H NMR (300 MHz, CDCl3; Bruker Avance 300 spectrometer):
dPLGA-Mal = 6.7 ppm (─HC─CH─), 5.2 ppm [─OCH(CH3)COO─],
and 1.6 ppm [─OCH(CH3)CO─].
Peptide-modified PLGA synthesis
All peptides used in this study were synthesized via solid phase peptide
synthesis as described elsewhere (15, 16).




Peptide (2.25 mmol) was added to 2.05 mmol of PLGA-NHS (for
g7-PLGA synthesis) or PLGA-Mal (for Ang2-PLGA and Tf2-PLGA
synthesis) in N,N′-dimethylformamide. The mixture was stirred at
room temperature for 18 hours (g7-PLGA) or 48 hours (Ang2-PLGADel Grosso et al., Sci. Adv. 2019;5 : eaax7462 20 November 2019and Tf2-PLGA). The final product was precipitated with methanol,
collected by centrifugation, and washed twice with methanol. The re-
actions were monitored via 1H NMR in CDCl3 (300 MHz; Bruker
Avance 300 spectrometer) until the absence of the NHS or the malei-
mide group d, indicating complete conversion. The final products were
dried and stored at −20°C until use.
Fluorophore-tagged PLGA synthesis
ATTO 633 amine (0.24 mmol) was added to 0.22 mmol of PLGA-NHS
in DMSO. The mixture was stirred for 18 hours at room temperature,
and the final product was precipitated with methanol and collected by
centrifugation. The obtained labeled PLGA was washed twice with
methanol, dried, and stored at −20°C until use.
rm-GALC production
Human embryonic kidney 293T cells stably expressing and secreting
His6-taggedmurineWTGALC (provided by J. Deane of the Cambridge
University) (42) were maintained in 400 mM zeocin selection medium
and expanded in 1450-cm2 inner surface roller bottles (37°C, 5% CO2,
0.7 rpm). The enzymewas routinely purified fromextracellularmedium
by nickel affinity chromatography (Ni Sepharose excel histidine-tagged
protein purification resin; 17-3712-03, GE Healthcare Life Sciences) as
in (13). The purified enzyme was lastly buffer-exchanged with 10 kDa
molecular mass cut-off concentrator and stored at −20°C until use.
CLEAs synthesis
To produceGALCCLEAs, typically 200 ml of GALC solution [750 mg/ml
in 10 mM mannitol, 5 mM glycine, 140 mM NaCl, 3.7 mM sodium
phosphate buffer, and 0.05% Tween 80 (pH 5.5)] was added to 600 ml
of acetone simultaneously with 2 ml of 25% glutaraldehyde under stirring.
The mixture was then stirred overnight at 4°C. The formed CLEAs were
centrifuged (30 min, 4°C, 13200 rpm) and washed twice with 1 ml of ac-
etone. The final GALC CLEAs were suspended in 1 ml of acetone and
stored at−20°C until use. To produce fluorescently labeledGALCCLEAs,
ATTO488–NHSsolution inDMSO(10mg/ml)was added to1mlofGALC
CLEAs with 1:20 CLEAs:ATTO 488–NHS molar ratio. The mixture was
stirred for 4 hours at room temperature, centrifuged (30 min, 13200 rpm),
and washed twice with 1 ml of acetone. Resulting ATTO 488–tagged
CLEAswere suspended in 1ml of acetone and stored at−20°C until use.
CLEA NPs synthesis
For targetedNP synthesis, 200 ml of GALCCLEAswere added to 200 ml
of a solutioncontaining8mgofPLGA752Hand2mgofpeptide-modified
PLGA in acetone. This mixture was then added dropwise to 1200 ml of
2% sodium cholate in water under stirring. The formed NP suspension
was centrifuged (20min, 4°C, 13200 rpm) andwashed twicewith 500 ml
of water. The final NP pellet was suspended in 50 ml of D-(+)-trehalose
(100 mg/ml) and stored at −20°C until use. To produce nontargeted
NPs, peptide-modified PLGA was replaced with the same amount of
PLGA 503H.
Fluorescently labeled NPs were obtained, adding 0.1 mg of ATTO
633–taggedPLGAand replacingGALCCLEAswithATTO488–tagged
GALC CLEAs. Empty NPs were produced, replacing GALC CLEAs
with the same volume of acetone.
Hydrodynamic diameter and zeta potential
Hydrodynamic diameter and zeta potential of NPs were measured
with a Zetasizer NanoZS (Malvern Instruments Inc., UK) by means
of dynamic light scattering. Samples were diluted 1:1000 in deionized
water before measurement. Samples were transferred into polypropylene
cuvettes for hydrodynamic diameter measurement or into appropri-
ate electrophoretic cells for zeta potential determination. Measure-
ments were performed at room temperature. Mean hydrodynamic
diameter resulted from the autocorrelation function of the intensity10 of 13









of scattered light calculated by DTS Nano software. Electrophoretic
mobility was determined and converted into zeta potential by DTS
Nano software.
Protein quantitation
GALC concentration in NP samples was determined via ninhydrin as-
say. Briefly, 5 ml of NPs were digested overnight at 95°C in 200 ml of 6M
HCl and then vacuum dried. The residue was suspended in deionized
water, and 10 ml of each sample was added to 110 ml of ninhydrin re-
agent [ninhydrin (20 mg/ml) and stannous chloride (2 mg/ml) in 75%
ethylene glycol in 4N acetate buffer (pH 5.5)]. The reactionmixture was
heated at 95°C for 20 min, and samples were plated into a 96-well mi-
croplate. Absorbance was measured at 560 nm.
Protein concentration was calculated by interpolation from a cali-
bration curve prepared with GALC subject to the same digestion and
reaction protocols.




where GALC(mg)NPs is the amount of GALC encapsulated in NPs and
GALC (mg)INJ is the amount of GALC used in each synthesis.
GALC activity measurement in NPs
To determine GALC activity in NP samples, 2 ml of NPs was added to
50 ml of assay buffer [50 mM sodium citrate, 125 mMNaCl, and 0.5%
Triton X-100 (pH 4.5)]. Then, 50 ml of 1 mM 4-methylumbelliferyl-
b-D-galactopyranoside in assay buffer was added. Samples were incu-
bated at 37°C for 20 min, and 200 ml of stop solution (0.5 M glycine,
0.3MNaOH)was added. Samples were plated into a 96-well multiplate
for fluorescence, and fluorescence was measured with the Promega
GloMax discoverMultimodemicroplate reader with an excitation filter
of 365 nm and an emission filter of 415 to 485 nm.
Activity yield (AY%) of NPs was calculated as the ratio between the
specific activity of the sample (SANPs) and the specific activity of the




where the specific activities are defined as unit of enzyme (U) per mi-
crogram of enzyme (mgGALC)
SA ¼ U
mgGALC
One unit of enzyme (U) is defined as 1 nmol of substrate (nmolSUB)
hydrolyzed in 1 hour
1U ¼ 1 nmolSUB
h
Primary human and murine cell cultures and treatments
Adult mouse fibroblast cultures were obtained fromWT and TWI ears,
according to the protocol established in the laboratory of E. Eichler
(University of Washington; https://genome.ucsc.edu/ENCODE/
protocols/cell/mouse/Fibroblast_Stam_protocol.pdf) with minor
modifications. Briefly, after anesthesia, mouse ears were extracted,
washedwith sterile water, and cut into small pieces. All pieces were then
collected in a tube and added with collagenase XI (C7657-100 mg;Del Grosso et al., Sci. Adv. 2019;5 : eaax7462 20 November 2019Sigma-Aldrich) diluted in high glucose Dulbecco’s modified Eagle me-
dium (DMEM) [approximately 2.5 mg of collagenase, 320 collagen
digestion units (CDU), for one mouse]. After 2 hours of incubation
at 37°C, the Eppendorf tube was centrifuged for 5 min at 200g, the
supernatant was discarded, and the pellet was washed with 2 ml of
PBS and centrifuged again, discarding the supernatant. Trypsin-
EDTA 0.05% (59418C-100ML, Thermo Fisher Scientific) was then
added to the tube and left for 45 min at 37°C. The tube was then cen-
trifuged, and the pellet was resuspended in the complete DMEM
[high-glucose DMEM supplemented with 10% of heat-inactivated fetal
calf serum (FCS), 4 mM L-glutamine, and 1% penicillin/streptomycin;
all products were from Gibco, Life Technologies)]. Obtained cells were
thus dissociated, pipetting up and down with a 10-ml syringe (with a
21 gauge needle), plated in a 60-mm cell petri dish, and incubated at
37°C in a humidified atmosphere containing 5%CO2. The day after, cells
were washed, and medium was replaced. After reaching confluence (ap-
proximately 3 to 4days), cells (p0)werewashedwith 1ml ofPBS and split
with a ratio of 1:2. Human fibroblasts [from anHD (C0045C, Life Tech-
nologies) and from a patient with the large common Caucasian 30-
kDa deletion in the GALC gene, c.1161+6532_polyA+9kbdel
(30kbD; F0461990, Gaslini Institute Biobank)] (39) were donated by
Gritti (SanRaffaele Telethon Institute for Gene Therapy,Milan, Italy)
and maintained under the just mentioned culture conditions. For
experiments, WT, TWI, 30kbD, and HD fibroblast cells were plated
in standard 96-well cell plates (12,500 cell per well). Twenty-four hours
later, medium was replaced with fresh medium containing NPs at dif-
ferent concentrations. After 4 hours of NPs incubation, medium was
removed, and cells were washed three times with 100 ml of PBS. Then,
cells were lysed for the enzymatic assay or freshmediumwas added, and
cells were lysed after 24 or 96 hours. For everyNP experiment,male and
female strains were used for experiments withmice cells; a female strain
was used for experiments with human cells. WT and TWI cells were
used at passage 4, and 30kbD andHD cells were used at passage 8 (43).
GALC enzymatic activity assay in cell and tissues
GALC enzymatic activity assay was carried out both in murine/human
fibroblasts and mouse tissues (brain, liver, kidney, sciatic nerve, and
spinal cord). Both primary cells and tissues were lysed on ice with
radioimmunoprecipitation assay (RIPA) buffer (Sigma-Aldrich) con-
taining a protease and phosphatase inhibitors cocktail (cOmplete and
PhosSTOP, RocheDiagnostics). Cell lysates were sonicated (for 4 s at
12 mm of intensity), whereas tissues were homogenized in 1.5 ml of
Eppendorf tube with appropriate micropestles. Then, after centrifuga-
tion (15,000g for 25 min at 4°C), the supernatants were collected and
tested for protein concentration by themicro-bicinchoninic acid (BCA)
Protein Assay Kit (Thermo Scientific Pierce). To measure GALC ac-
tivity, we used 6-hexadecanoylamino-4-methylumbelliferyl-b-D-
galactopyranoside (HMU-bGal), the fluorescent substrate currently
used for the clinical diagnosis of KD (44): 10 ml of lysates was
added to 20 ml of 50 mMHMU-bGal substrate solution, incubated
for 17 hours at 37°C. The reaction was then stopped, and the flu-
orescent product [4-methylumbelliferone (4-MU)] was read by
using the microplate GloMax fluorescence reader. GALC activity (re-
ported as nanomole per milligram protein extract in 17 hours of in-
cubation) was calculated by comparison with a standard curve
previously obtained by measuring the fluorescence of different concen-
tration of 4-MU.
Animal procedures
TWI heterozygous mice (TWI+/− C57BL6 mice; the Jackson Labo-
ratory), donated by A. Biffi (San Raffaele Telethon Institute for11 of 13









Gene Therapy, Milan, Italy), were used as breeder pairs to generate
homozygous TWI mice (TWI−/−, elsewhere abbreviated as TWI for
simplicity). Animals were maintained under standard housing
conditions and used according to the protocols and ethical guide-
lines approved by the Ministry of Health (permit no. Codice 535/
2018-PR; official starting date: 9 July 2018). For genotyping purpose,
mice genomicDNAwas extracted from clipped tails ofmice at post-natal
day (PND) 10 to 15 (EUROGOLD Tissue-DNA Mini Kit, EURO-
CLONE), as previously done by us (45). The genetic status of each
mouse was later determined from the genome analysis of the TWImu-
tation, as reported fromSakai and co-workers (46). TWI,WT, andHET
animals (PND 19 to 21) were used for experiments. TWI animals were
intraperitoneally injected with NPs (1600 mg/kg) or with free GALC
(100 mg/kg) diluted in 1 ml of physiological solution (3, 47). After
4 hours,micewere deeply anesthetizedwith a urethane solution (0.8ml/
Hg; Sigma-Aldrich) and euthanized by transcardial perfusion with
PBS so as to remove the blood from vessels. Subsequently, the brain
and liver were extracted from each mouse, and one brain hemisphere
or liver lobe was placed in 4% PFA solution and the other hemisphere
or liver lobe in RIPA lysis buffer (R0278-50ML, Sigma-Aldrich)
containing a protease and phosphatase inhibitors cocktail [cOmplete
(4693116001) and PhosSTOP (4906845001), Roche Diagnostics].
The spinal cord, sciatic nerve, and kidneys were also extracted and
stored in the complete RIPA buffer previously described. Last, organs
placed in the PFA solution were stored at 4°C for a minimum of 3 days
before vibratome cutting, whereas organs put in the lysis buffer were
immediately processed to perform the GALC enzymatic assay. Regard-
ing mice sex, experiments were done as follows: First, five WT male,
seven WT female, four TWI male, three TWI female, one HET male,
and two HET female were used for the untreated conditions. Second,
three TWI male and three TWI female were used for the targeted-
GALC loaded NPs injections (one male and one female for each tar-
geting peptide: g7, ANG2, or Tf2). Last, two TWI male and two TWI
female were used for the control conditions (onemale and one female
for nontargeted GALC-loaded NPs and for the free GALC). All pro-
cedures were made with the maximal efforts to minimize mice
suffering.
Cells and tissues confocal imaging
TWI orWT fibroblasts were seeded 24 hours before experiments into a
glass-bottom petri dish (WillCo-dish GWST-3522) to reach 80 to 90%
confluence. Incubationwith targeted or nontargetedGALC-loadedNPs
was performed at 37°C with 5% CO2 in DMEM with 10% FCS at final
NP concentration of 1.5 mg/ml. After 4 hours, cells were washed twice
with PBS and incubated with fresh medium for 20 hours. Then, cells
were incubated with 0.1 mMLysoTracker RedDND-99 (Thermo Fisher
Scientific). After 15 min, cells were washed with PBS and stained with
4% PFA before imaging.
For tissue imaging, the brain and liver samples were processed as
described in the animal procedure paragraph. Samples were cut with
a vibratome (Leica VT1000 S) at a final slice thickness of 60 mm. In par-
ticular, consecutive coronal brain sections were cut at 0.5 to 2.10 mm
from bregma.
All samples were mounted with Fluoroshield mounting medium
with 4′,6-diamidino-2-phenylindole. Samples were imaged with a Leica
TCS SP5 SMD inverted confocal microscope (Leica Microsystems AG)
interfaced with Ar, diode-pumped solid-state (DPSS), and HeNe lasers
for excitation at 488, 560, and 633 nm, respectively, andwith an external
pulse diode laser for excitation at 405 nm. Samples were viewed with a
40× 1.5 numerical aperture oil immersion objective (LeicaMicrosystems)Del Grosso et al., Sci. Adv. 2019;5 : eaax7462 20 November 2019with pinhole aperture set at 1.0 Airy. All images were analyzed with Fiji
software, and colocalization was determined with JACoP plugin.
Statistical analysis
If not differently specified, data are reported as means ± SEM obtained
from at least three independent experiments (in figure legends, “n” in-
dicates the number of experiments performed). Data were statistically
analyzed by using Prism 6.00 (GraphPad Software, San Diego, CA;
RRID:SCR_002798). For parametric data, Student’s t test (unpaired,
two tailed) or one-way analysis of variance (ANOVA) (Tukey’s or
Dunnett’s multiple comparisons test) was used; the mean values ob-
tained in each repeated experiment were assumed to be normally dis-
tributed about the true mean. Statistical significance refers to results
for which P < 0.05 was obtained.SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/5/11/eaax7462/DC1
Fig. S1. Intracellular localization of targeted GALC CLEA NPs in WT cells.
Fig. S2. Untreated WT and TWI fibroblasts.
Fig. S3. GALC-loaded NPs activity over time in the presence and absence of serum proteins.
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